Gut barrier function in Alzheimer’s disease
阿尔茨海默病中的肠道屏障功能
基本信息
- 批准号:10614373
- 负责人:
- 金额:$ 73.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-15 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAgeAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease pathologyAlzheimer&aposs disease related dementiaAlzheimer’s disease biomarkerAmyloidAmyloid beta-42Antibody titer measurementAutomobile DrivingBiological AssayBiological MarkersBlood - brain barrier anatomyBrainCerebrospinal FluidChemicalsCirculationClinicalCognitiveCollectionDementiaDerivation procedureDevelopmentDiseaseDisease ProgressionElderlyFRAP1 geneGastrointestinal tract structureGerm-FreeGnotobioticGoalsHomeostasisHumanImmune responseImmune systemImpairmentIndividualInfrastructureInnate Immune ResponseIntestinal permeabilityIntestinesLactuloseLeukocyte L1 Antigen ComplexLinkLipopolysaccharidesLiquid substanceMannitolMeasuresMediatingMethodsMicrobeMicrobiologyMucous body substanceMusNerve DegenerationNeurodegenerative DisordersParticipantPathogenesisPathologyPermeabilityPersonsPlayPositron-Emission TomographyProcessPublishingReportingResearchResourcesRoleSamplingSignal TransductionSodium Dextran SulfateSystemTestingTherapeuticTimeUnited StatesWisconsinWorkage relatedamyloid pathologyblood-brain barrier permeabilizationcohorteffective therapyexperimental studyglial activationgut dysbiosisgut inflammationgut microbesgut microbiomegut microbiotaindexinginflammatory markerintestinal barriermacromoleculemetagenomemicrobialmicrobiome compositionmouse modelneuroimmunologyneuropathologynovel therapeutic interventionparticipant enrollmentprospectivesuccesssystemic inflammatory responsetau Proteinsvirtual
项目摘要
The age-related processes that contribute to Alzheimer's disease (AD) development, particularly in the
prodromal period, are incompletely understood. Age-related reduction in gut microbiome alpha-diversity is
apparent in the majority of older adults, and is suspected of contributing to brain changes, including the
development of neurodegenerative disease. Our team published the first comprehensive report describing
differences in the gut microbiome observed in AD dementia, including reduced diversity in gut microbiota and
altered composition in people with AD dementia compared to age-matched controls. Furthermore, we found that
differentially abundant genera were associated with cerebrospinal fluid biomarkers of AD, even among
individuals who were cognitively unimpaired. Several studies in mouse models of AD indicate that gut microbiota
play a role in the development of AD neuropathology, however to date, the mechanisms underlying these effects
are virtually unknown. Recently it has also become clear that the innate immune response in AD plays a critical
role in mediating the pathology associated with AD; however the interplay between systemic changes and the
innate immune response in AD are not well understood, nor is it known how these factors impact the progression
of AD pathology. Our overarching goal is to determine the extent to which alterations in the composition of gut
microbiome exacerbate and/or accelerate the development of AD pathology. This proposal is based on the
central hypothesis that age-associated gut dysbiosis and inflammation weaken gut barrier function, which in turn
leads to the systemic dissemination of microbial components, driving an immune response and system wide
changes that worsen AD pathology. To test this hypothesis we propose to study well-characterized participants
enrolled in the Wisconsin Alzheimer's Disease Research Center as well as conventional and gnotobiotic
APPPS1 mice, to address the following specific aims: 1. Determine the longitudinal relationship between gut
microbiome (metagenome), gut inflammation and permeability, and the development of AD pathology in
human participants, and 2. Determine the effects of modifying gut permeability on AD pathology in mice.
We expect that alterations in gut microbiome composition and gut permeability exacerbate AD pathology in
humans, and that impairment of intestinal barrier function and increased gut permeability alters brain
homeostasis and exacerbates AD progression in mouse models of AD. Our research group has been working
to determine the role of gut microbiome in the development of AD pathology for the past 5 years, and we are
perfectly poised to address the proposed aims. We will leverage our expertise in clinical AD, neuroimmunology,
and gut microbiology/gnotobiotic mouse models to successfully carry out the proposed project. Completion of
the proposed experiments is expected to lead to the development of novel therapeutic strategies for AD and
related dementias.
导致阿尔茨海默病(AD)发展的年龄相关过程,特别是在
前驱期,都是不完全了解。与年龄相关的肠道微生物群α多样性降低是
在大多数老年人中都很明显,并被怀疑导致了大脑的变化,包括
神经退行性疾病的发展。我们的团队发布了第一份全面的报告,描述了
在AD痴呆患者中观察到的肠道微生物群的差异,包括肠道微生物区系和
与年龄匹配的对照组相比,AD痴呆症患者的成分发生了变化。此外,我们发现,
差异丰富的属与AD的脑脊液生物标志物有关,甚至在
认知能力未受损的个人。对阿尔茨海默病小鼠模型的几项研究表明,肠道微生物区系
在AD神经病理学的发展中发挥作用,然而,到目前为止,这些影响的机制
几乎是未知的。最近也清楚地表明,AD的先天免疫反应在其中起着至关重要的作用
在与AD相关的病理中的作用;然而,系统性变化和
AD的先天免疫反应还不是很清楚,也不知道这些因素是如何影响进展的
AD病理学的研究。我们的首要目标是确定肠道成分的变化程度
微生物组可加重和/或加速AD的病理发展。这项建议是基于
中心假设与年龄相关的肠道生物失调和炎症会削弱肠道屏障功能,进而削弱肠道屏障功能。
导致微生物成分的系统性传播,推动免疫反应和整个系统
使AD病理恶化的变化。为了验证这一假设,我们建议研究特征良好的参与者。
加入威斯康星州阿尔茨海默病研究中心,以及传统和灵知生物
APPPS1小鼠,针对以下具体目的:1.确定肠道的纵向关系
微生物组(超基因组)、肠道炎症和通透性与AD的病理发展
2.确定改变肠道通透性对小鼠AD病理的影响。
我们预计肠道微生物组组成和肠道通透性的改变会加剧AD的病理。
肠道屏障功能受损和肠道通透性增加会改变大脑
在阿尔茨海默病小鼠模型中,动态平衡和加剧阿尔茨海默病的进展。我们的研究小组一直在努力
以确定肠道微生物群在过去5年AD病理发展中的作用,我们正在
完全准备好实现拟议的目标。我们将利用我们在临床AD、神经免疫学、
并成功开展了肠道微生物学/灵芝小鼠模型的拟议项目。完成
拟议的实验有望导致开发AD和AD的新治疗策略
相关痴呆症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Barbara Brigitta Bendlin其他文献
Barbara Brigitta Bendlin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Barbara Brigitta Bendlin', 18)}}的其他基金
ß-hydroxybutyrate inhibition of pathology in Alzheimer's disease
α-羟基丁酸对阿尔茨海默病病理学的抑制作用
- 批准号:
10739679 - 财政年份:2023
- 资助金额:
$ 73.99万 - 项目类别:
Administrative Supplement to Establish National Exposome Alzheimer's Disease and Related Dementias (ADRD) Infrastructure (Expo-AD)
建立国家阿尔茨海默氏病和相关痴呆症 (ADRD) 基础设施 (Expo-AD) 的行政补充
- 批准号:
10658250 - 财政年份:2021
- 资助金额:
$ 73.99万 - 项目类别:
The Neighborhoods Study: Contextual Disadvantage and Alzheimer’s Disease and Related Dementias (ADRD)
社区研究:环境劣势与阿尔茨海默病及相关痴呆症 (ADRD)
- 批准号:
10803585 - 财政年份:2021
- 资助金额:
$ 73.99万 - 项目类别:
The Neighborhoods Study: Contextual Disadvantage and Alzheimer’s Disease and Related Dementias (ADRD)
社区研究:环境劣势与阿尔茨海默病及相关痴呆症 (ADRD)
- 批准号:
10361428 - 财政年份:2021
- 资助金额:
$ 73.99万 - 项目类别:
The Neighborhoods Study: Contextual Disadvantage and Alzheimer’s Disease and Related Dementias (ADRD)
社区研究:环境劣势与阿尔茨海默病及相关痴呆症 (ADRD)
- 批准号:
10580795 - 财政年份:2021
- 资助金额:
$ 73.99万 - 项目类别:
SV2A PET imaging in Alzheimer's Disease
SV2A PET 成像在阿尔茨海默病中的应用
- 批准号:
9919489 - 财政年份:2018
- 资助金额:
$ 73.99万 - 项目类别:
SV2A PET imaging in Alzheimer's Disease
SV2A PET 成像在阿尔茨海默病中的应用
- 批准号:
10403978 - 财政年份:2018
- 资助金额:
$ 73.99万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 73.99万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 73.99万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 73.99万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 73.99万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 73.99万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 73.99万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 73.99万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 73.99万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 73.99万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 73.99万 - 项目类别:
Research Grant














{{item.name}}会员




